Maria Haque
Cardiotoxicity of breast cancer drug treatments
Haque, Maria; Atallah, Nehal; Patke, Rodhan; Harris, Anna E.; Woodcock, Corinne L.; Varun, Dhruvika; Thompson, Rachel L.; Jackson-Oxley, Jorja; Okui, Cyntholia H.; Dean, Alexander; Alsaleem, Mansour; Rakha, Emad; Irshad, Sheeba; Davis, Melissa B.; Jeyapalan, Jennie N.; Mongan, Nigel P.; Rutland, Catrin S.
Authors
Dr NEHAL ATALLAH Nehal.Atallah1@nottingham.ac.uk
RESEARCH ASSOCIATE
Rodhan Patke
Dr ANNA HARRIS Anna.Harris@nottingham.ac.uk
RESEARCH FELLOW
Dr CORINNE WOODCOCK CORINNE.WOODCOCK1@NOTTINGHAM.AC.UK
RESEARCH FELLOW
Dhruvika Varun
Rachel L. Thompson
Jorja Jackson-Oxley
Cyntholia H. Okui
Alexander Dean
Mansour Alsaleem
Professor EMAD RAKHA Emad.Rakha@nottingham.ac.uk
PROFESSOR OF BREAST CANCER PATHOLOGY
Sheeba Irshad
Melissa B. Davis
Dr JENNIE JEYAPALAN jennie.jeyapalan@nottingham.ac.uk
ASSISTANT PROFESSOR
Professor Nigel Mongan nigel.mongan@nottingham.ac.uk
ASSOCIATE PRO-VICE CHANCELLORGLOBAL ENGAGEMENT
Professor CATRIN RUTLAND CATRIN.RUTLAND@NOTTINGHAM.AC.UK
PROFESSOR OF MOLECULAR MEDICINE
Abstract
Breast cancer (BC) is a leading cause of cancer-related mortality among women worldwide. BC is regarded as a systemic disease. Consequently, the majority of BC patients undergo systemic therapy to reduce the risk of distant metastasis (DM) and associated mortality. Although systemic therapies improve patients’ outcome, they are associated with significant side effects, particularly cardiotoxicity and cardiovascular complications. Such side effects vary significantly in severity and duration. Cardiotoxicity may remain undetected for years post-treatment until the symptoms of heart failure (HF) present in the patient, which can reduce life expectancy, quality of life, and even lead to death. Therefore, it is vital to investigate the cardiotoxic and cardiovascular risks of BC treatment regimens to identify patients who would benefit most from cardiac monitoring. As it stands, cardiotoxicity is reported from individual studies or for selected drug therapies only. This review fulfils a gap in the literature by combining clinical studies of cardiotoxicity together from clinical trial data published on clinicaltrials.gov.uk.
Citation
Haque, M., Atallah, N., Patke, R., Harris, A. E., Woodcock, C. L., Varun, D., Thompson, R. L., Jackson-Oxley, J., Okui, C. H., Dean, A., Alsaleem, M., Rakha, E., Irshad, S., Davis, M. B., Jeyapalan, J. N., Mongan, N. P., & Rutland, C. S. (2025). Cardiotoxicity of breast cancer drug treatments. Translational Oncology, 55, Article 102352. https://doi.org/10.1016/j.tranon.2025.102352
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 4, 2025 |
Online Publication Date | Mar 15, 2025 |
Publication Date | 2025-05 |
Deposit Date | Mar 24, 2025 |
Publicly Available Date | Mar 25, 2025 |
Journal | Translational Oncology |
Electronic ISSN | 1936-5233 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 55 |
Article Number | 102352 |
DOI | https://doi.org/10.1016/j.tranon.2025.102352 |
Public URL | https://nottingham-repository.worktribe.com/output/46994628 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S193652332500083X?via%3Dihub |
Files
1-s2.0-S193652332500083X-main
(4.6 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search